The risks and benefits of antidepressant use in patients with major depressive disorder (MDD) have been highlighted

By  

Inpharma, Vol. 1, Iss. 1461, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

By  

Current Neuropharmacology, Vol. 12, Iss. 5, 2014-09 ,pp. : 387-398

Bentham Science Publishers

Access to resources Recommend Favorite

Sertraline: A Review of its Use in the Management of Major Depressive Disorder in Elderly Patients

By Muijsers R.B.R.   Plosker G.L.   Noble S.  

Drugs & Aging, Vol. 19, Iss. 5, 2002-05 ,pp. : 377-392

Adis International

Access to resources Recommend Favorite

Catechol-O-Methyltransferase (COMT) Pharmacogenetics in the Treatment Response Phenotypes of Major Depressive Disorder (MDD)

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 264-272

Bentham Science Publishers

Access to resources Recommend Favorite

Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature

By Mancini Michele   Perna Giampaolo   Rossi Andrea   Petralia Antonino  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1167-1181

Informa Healthcare

Access to resources Recommend Favorite